Changes in PD-L1 expression on microvessel endothelial cells during melanoma tumor growth and the regulation by anlotinib

Yingfang Feng(Tianjin Medical University Cancer Institute and Hospital), Kai Li(Guangdong Academy of Medical Sciences)

Research Square

August 10, 2023

10.21203/rs.3.rs-3231581/v1

Cited by 0

Related Papers

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

|Cell Death and Disease|2020|185

<p>Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation</p>

|OncoTargets and Therapy|2020|16

Immune‐independent acquired resistance to <scp>PD‐L1</scp> antibody initiated by <scp>PD‐L1</scp> upregulation via <scp>PI3K</scp>/<scp>AKT</scp> signaling can be reversed by anlotinib

|Cancer Medicine|2023|13

Genomic alteration profile and <scp>PD‐L1</scp> expression among different breast cancer subtypes in Chinese population and their correlations

|Cancer Medicine|2022|4